Related Experiment Video
Updated: Jul 5, 2025
Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
Published on: July 26, 2017
Nanomaterial-mediated modulation of the cGAS-STING signaling pathway for enhanced cancer immunotherapy
Yaxin Wang1, Yunmeng Liu1, Jincheng Zhang1
1College of Pharmacy, Nankai University, Tianjin 300350, PR China.
Abstract:
Despite the current promise of immunotherapy, many cancer patients still suffer from challenges such as poor immune response rates, resulting in unsatisfactory clinical efficacy of existing therapies. There is an urgent need to combine emerging biomedical discoveries and innovations in traditional therapies. Modulation of the cGAS-STING signalling pathway represents an important innate immunotherapy pathway that serves as a crucial DNA sensing mechanism in innate immunity and viral defense. It has attracted increasing attention as an emerging target for cancer therapy. The recent advancements in nanotechnology have led to the significant utilization of nanomaterials in cancer immunotherapy, owing to their exceptional physicochemical properties such as large specific surface area and efficient permeability. Given the rapid development of cancer immunotherapy driven by the cGAS-STING activation, this study reviews the latest research progress in employing nanomaterials to modulate this signaling pathway. Based on the introduction of the main activation mechanisms of cGAS-STING pathway, this review focuses on nanomaterials that mediate the agonists involved and effectively activate this signaling pathway. In addition, combination nanotherapeutics based on the activation of the cGAS-STING signaling pathway are also discussed, including emerging strategies combining nanoformulated agonists with chemotherapy, radiotherapy as well as other immunomodulation in tumor targeting therapy. STATEMENT OF SIGNIFICANCE: Given the rapid development of cancer immunotherapy driven by the cGAS / STING activation, this study reviews the latest research advances in the use of nanomaterials to modulate this signaling pathway. Based on the introduction of key cGAS-STING components and their activation mechanisms, this review focuses on nanomaterials that can mediate the corresponding agonists and effectively activate this signaling pathway. In addition, combination nanotherapies based on the activation of the cGAS-STING signaling pathway are also discussed, including emerging strategies combining nanoformulated agonists with chemotherapy, radiotherapy as well as immunomodulation in cancer therapy,.
Insights
Nanomaterials are emerging as a powerful tool to enhance cancer immunotherapy by modulating the cGAS-STING pathway. This review explores how nanotechnology combined with agonists can improve treatment efficacy and overcome current limitations.
Area of Science:
- Immunology
- Nanotechnology
- Oncology
Background:
- Current immunotherapies face challenges with low response rates and limited efficacy in many cancer patients.
- The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling pathway is a critical innate immune sensor for DNA, offering a promising target for cancer therapy.
- Nanomaterials offer unique properties for drug delivery and therapeutic modulation in cancer treatment.
Purpose of the Study:
- To review the latest advancements in using nanomaterials to modulate the cGAS-STING signaling pathway for cancer immunotherapy.
- To discuss how nanomaterials can mediate agonists to activate the cGAS-STING pathway.
- To explore combination nanotherapeutics that leverage cGAS-STING activation with other cancer treatments.
Main Methods:
- Review of current research on nanomaterial applications in cGAS-STING pathway modulation for cancer immunotherapy.
- Analysis of nanomaterials that mediate agonists for effective cGAS-STING pathway activation.
- Discussion of combination strategies involving nanoformulated agonists with chemotherapy, radiotherapy, and other immunomodulatory approaches.
Main Results:
- Nanomaterials show significant potential in enhancing cancer immunotherapy by targeting the cGAS-STING pathway.
- Various nanomaterials can effectively mediate agonists to activate the cGAS-STING signaling cascade.
- Combination nanotherapies integrating nano-agonists with conventional treatments demonstrate promising synergistic effects.
Conclusions:
- Nanomaterial-based modulation of the cGAS-STING pathway represents a significant advancement in cancer immunotherapy.
- These strategies offer a promising avenue to overcome the limitations of current cancer treatments and improve clinical outcomes.
- Further research into combination nanotherapeutics holds great potential for developing more effective tumor-targeting strategies.
